Table 4 Stratification by anti-hypertensive medication use of the immune cell subsets with a statistically significant main effect to test for effect measure modification

Any antihypertensive medication use (median SBP 131 mmHG) n = 1852 repeated SBP measures

 CD3⁺ γδ⁺

5.10

3.03

7.17

 < .0001

 CD3⁻ CD56⁺ CD16⁺

2.25

1.06

3.45

0.0002

 CD14⁺⁺ CD16⁻

− 2.02

− 3.61

− 0.43

0.0127

 CD14⁺ CD16⁺

1.16

− 0.41

2.74

0.1475

 CD14_DimCD16⁺⁺

1.52

0.019

3.30

0.0472

No antihypertensive medication use (median SBP 119.5 mmHG) n = 1928 repeated SBP measures

 CD3⁺ γδ⁺

1.33

0.22

2.45

0.0194

 CD3⁻ CD56⁺ CD16⁺

0.76

− 0.67

2.19

0.2997

 CD14⁺⁺ CD16⁻

− 0.79

− 2.22

0.63

0.2756

 CD14⁺ CD16⁺

− 0.38

− 1.76

1.00

0.5912

 CD14_DimCD16⁺⁺

1.56

− 0.027

3.15

0.0540